XBB .1.5‐Adapted COVID ‐19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS ‐ CoV ‐2 JN .1 Variant in Patients With Inflammatory Bowel Disease
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.18349 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Simon Woelfel und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, COVID-19 Vaccines, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: University of Oxford, HORIZON Europe European Research Council, State Ministry of Baden-Württemberg for Economic Affairs, Labor, and Tourism.
Abstract (Originalsprache)
Background
Variant‐adapted COVID‐19 vaccines are recommended for patients with inflammatory bowel disease (IBD). However, many patients rely on pre‐existing immunity by original vaccines or prior infections.
Aim
To assess whether such immunity sufficiently combats the highly immune‐evasive SARS‐CoV‐2 JN.1 variant.
Methods
Utilising two longitudinal cohorts, we evaluated immunity against JN.1 induced by original vaccines (IBD: n = 98; healthy: n = 48), omicron breakthrough infection (IBD: n = 55; healthy: n = 57) or XBB.1.5‐adapted vaccines (IBD: n = 18). Neutralisation and anti‐receptor‐binding domain (RBD) IgG levels against wild‐type SARS‐CoV‐2 and JN.1 were assessed using multiplex immunoassays. Study outcomes were wild‐type and JN.1 neutralisation following three doses of original mRNA vaccines, stratified by immunosuppressive therapy (primary outcome), and JN.1 neutralisation following third‐dose breakthrough infection or a fourth dose of XBB.1.5‐adapted mRNA vaccines (secondary outcomes).
Results
Following original vaccines, JN.1 neutralisation was lower than wild‐type neutralisation in all study groups (healthy, anti‐TNF and non‐anti‐TNF; each p < 0.001); most individuals lacked JN.1 neutralisation (healthy: 97.9%; anti‐TNF: 98.3% and non‐anti‐TNF: 92.3%). Confounder‐adjusted multivariable modelling strongly associated anti‐TNF therapy with low levels of anti‐JN.1‐RBD IgG (fold‐change 0.48 [95% CI 0.39–0.59]). JN.1 neutralisation was similar in patients with or without breakthrough infection (anti‐TNF, non‐anti‐TNF; each p > 0.05); neutralisation failure was 100% despite breakthrough infection. XBB.1.5‐adapted vaccines enhanced JN.1 neutralisation ( p < 0.001) and reduced neutralisation failure rates in patients with IBD (94.4% pre‐vaccination vs. 44.4% post‐vaccination; p = 0.003).
Conclusions
Only variant‐adapted vaccines protect against emerging SARS‐CoV‐2 variants. Patients with IBD and healthy individuals without recent vaccination may lack protection against the JN.1 subvariant KP.3 which causes current COVID‐19 surges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
- Max von Pettenkofer Institute of Hygiene and Medical Microbiology, Faculty of Medicine, Ludwig Maximilian University of Munich, Munich, Germany.
- Outpatient Clinic, Ambulatory Services Rorschach, Rorschach, Switzerland.
- NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
- Clinical Trials Unit, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
- Department of Visceral Surgery and Medicine, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.
ORCID-Profile: Simon Woelfel, Stephan Brand
Förderung
- University of Oxford
- HORIZON Europe European Research Council
- State Ministry of Baden-Württemberg for Economic Affairs, Labor, and Tourism
- Cantonal Hospital St. Gallen
Zitieren
APA
Woelfel, S., Dütschler, J., Junker, D., König, M., Graf, N., Krieger, C., Truniger, S., Oikonomou, V., Leinenkugel, G., Koller, S., Metzger-Peter, K., Wyss, J., Krupka, N., Frei, N., STAR SIGN Study Investigators, Albrich, W. C., Friedrich, M., Niess, J. H., Schneiderhan-Marra, N., …, & Brand, S. (2025). XBB .1.5‐Adapted COVID ‐19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS ‐ CoV ‐2 JN .1 Variant in Patients With Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18349
Vancouver
Woelfel S, Dütschler J, Junker D, König M, Graf N, Krieger C, et al. XBB .1.5‐Adapted COVID ‐19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS ‐ CoV ‐2 JN .1 Variant in Patients With Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18349
BibTeX
@article{Woelfel2025,
author = {Woelfel, Simon and Dütschler, Joel and Junker, Daniel and König, Marius and Graf, Nicole and Krieger, Claudia and Truniger, Samuel and Oikonomou, Vasileios and Leinenkugel, Georg and Koller, Seraina and Metzger-Peter, Katline and Wyss, Jacqueline and Krupka, Niklas and Frei, Nicola and STAR SIGN Study Investigators, STAR SIGN Study Investigators and Albrich, Werner C and Friedrich, Matthias and Niess, Jan Hendrik and Schneiderhan-Marra, Nicole and Dulovic, Alex and Misselwitz, Benjamin and Korte, Wolfgang and Bürgi, Justus J and Brand, Stephan},
title = {XBB .1.5‐Adapted COVID ‐19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS ‐ CoV ‐2 JN .1 Variant in Patients With Inflammatory Bowel Disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.18349}
}
EUVIMED